Participated · Seed · Aug 2026

formX offers an AI-native platform that automates and coordinates design, engineering, planning, permitting, procurement, and construction workflows while allowing each home to remain fully customized. The company emphasizes standardizing the process behind residential projects rather than standardizing the homes themselves. Its platform is already deployed on residential projects in the San Francisco Bay Area. formX plans to use the Seed funding to accelerate product development and expand its engineering team. The company also intends to scale its technology more broadly across California. Founders named in the announcement are Gal Rozensweig, Shay Hasson, and Nami Gheidar. The announcement did not disclose revenue or user metrics.

Participated · Series A · Apr 2026

Quantum Art was spun out of Prof. Roee Ozeri's group at the Weizmann Institute of Science and is led by CEO and co-founder Dr. Tal David, CTO Dr. Amit Ben Kish and CSO Prof. Roee Ozeri. The company focuses on trapped-ion quantum computing and has developed proprietary techniques for multi-qubit gates, scalable modular architectures, and robust quantum error correction. It is advancing a multi-core roadmap including Perspective, a planned 1,000-qubit system aimed at commercial-scale deployment. Quantum Art is transitioning toward commercialization with plans for a Quantum-as-a-Service (QaaS) platform that lets customers move from algorithm development and co-design to execution on its hardware. The company said it is expanding internationally and building partnerships to support early customer adoption while hiring to support development and business growth.

Participated · Series D · May 2025

Buildots provides an AI and computer-vision platform that processes images captured from 360-degree cameras mounted on managers’ hard hats to track construction progress and forecast issues. The system includes a chatbot for project-status queries and predictive tools that alert teams to delay risks and pacing problems. Founded in 2018 and based in Chicago, the company counts Intel and roughly 50 construction firms among its clients. Buildots has grown to over 230 employees and plans to expand its North American operations with a focus on growing R&D teams. The company intends to use historical project data to train models that benchmark and optimize construction performance and to extend its product to cover more stages of the construction lifecycle. Buildots positions itself as an operations-focused platform for performance management in construction and competes with firms such as BeamUp and Versatile. Buildots is an Israel- and U.K.-based AI construction company that deploys 360-degree cameras and computer-vision models to build digital twins of job sites and track project progress. It works with large contractors such as Pomerleau, NCC and Ledcor to identify bottlenecks and optimize workflows. The company recently launched an AI-powered "delay forecast" feature that in beta tests reduced delay times by up to 50% in some scenarios. Buildots is six years old and has pursued multiple financings to scale its product and deployments. Prior to the new round it had raised around $106 million, including a $60 million tranche two years ago. The firm positions its technology as a way to drive efficiencies and cost savings on large, complex construction projects. Buildots, founded in 2018 by Roy Danon, Aviv Leibovici and Yakir Sudry, builds an AI platform that uses hardhat-mounted 360-degree cameras and computer vision to capture and analyze construction-site progress. The platform ingests project schedules, designs and site footage to generate a model of an active site and automatically compare on-site conditions to plans, with automated blurring of people for compliance. Buildots offers two-way integrations with planning tools including Oracle Primavera P6, Asta Powerproject and Microsoft Project to enable instant timeline updates and monthly progress reports to validate subcontractor payments. The company says it has operated across North America, Europe, Asia‑Pacific and the Middle East, collecting diverse datasets to improve its AI models. Buildots reported that revenue grew tenfold in 2021 while its customer base expanded to “dozens” of contractors. The team has more than doubled over the past year, recently surpassing 200 employees and planning to reach about 300 by the end of 2022; new funding will be used for product development and expansion in Europe and North America. Buildots is a three-year-old construction-technology company headquartered in Tel Aviv and London that uses AI and computer-vision to monitor construction sites via hardhat-mounted 360-degree cameras. Its algorithms automatically validate captured images against original designs and schedules to detect gaps and out-of-spec work, creating a single source of truth for project teams. The platform surfaces installation errors, helps streamline payments, and aims to reduce blaming and inefficiencies on sites. Buildots is deployed on major building projects across the U.S., U.K., Germany, Switzerland, Scandinavia and China and works with four of the top 10 construction companies globally. The company reported more than 50% quarter-over-quarter growth over the past year in three countries where it operates. To meet demand it plans to continue international expansion, double its global team with a focus on sales, marketing and R&D, and explore applications beyond construction. Buildots is a Tel Aviv- and London-based startup founded in 2018 that uses hardhat-mounted 360-degree cameras and computer vision to modernize construction management. Its software creates a digital twin from architectural plans and schedules and compares site imagery to detect missing fixtures or schedule deviations. The system handles construction-site constraints such as limited Wi‑Fi and three-dimensional positioning by using manual uploads and algorithms to determine floor-level context. The company has 35 employees and has expanded beyond Israel and the U.K. into projects in Poland and upcoming work in Japan. Financially, Buildots has raised $16M total (a previously unreported $3M seed plus a $13M Series A) led by TLV Partners. The team plans to scale the business and turn the data it collects into tools and workflows that support more roles on construction sites.

Participated · Series B · Mar 2023

Assured Allies is an insurtech focused on retirement savings and long-term care solutions that combines machine learning, predictive analytics, science-of-aging and human support. The company was founded in 2018 by Roee Nahir and Dr. Afik Gal and launched its first product, AgeAssured, in 2020 to partner with long-term care insurers and support aging-at-home. AgeAssured has been shown to reduce the cost of long-term insurance claims by roughly 20%. In 2022 Assured Allies introduced NeverStop, which uses artificial intelligence and science to create and underwrite retirement products. The business saw 300% growth in the number of members using its platform and secured partnerships with several leading long-term care insurance carriers over the prior year. Financially, it closed a $42.5M Series B and has now raised $65M in total capital. Management intends to deploy the new capital into further product growth and expansion of its carrier and partner network. Assured Allies develops technology and services to predict and shift the aging trajectory using a patent-pending method and a proprietary aging score. The company offers the Age Assured program and aims to combine wellness with financial products to make longevity financially sustainable. It provides evidence-based interventions to reduce the risk of age-related decline and help people get the most out of life. Assured Allies was founded in 2018 and is based in Boston, MA and Tel Aviv, Israel. The founding team includes CEO Roee Nahir and Chief Product Officer Afik Gal, MD. The company plans to continue developing new aging innovations and to accelerate delivery of its Age Assured program.

Participated · Equity · Jan 2022

MeMed develops rapid host immune-response diagnostic tests that decode the body’s immune signals to help clinicians distinguish bacterial from viral infections and predict COVID-19 severity. The company’s MeMed BV® test received FDA clearance for use on the point-of-need MeMed Key® platform to aid in distinguishing bacterial and viral infections in children and adults. MeMed also markets the MeMed COVID-19 Severity™ test, which has been cleared for use in Europe. The company says it will use new funding to scale manufacturing, accelerate commercialization and expand its host-response product portfolio, with a particular operational focus on the U.S. MeMed reports total funding now exceeds $200 million, including prior support from the U.S. Department of Defense and the EU Commission. The company maintains a presence in Haifa, Israel and Boston, MA. MeMed has developed and validated an immune-based protein signature called MeMed BV™ to distinguish between bacterial and viral infections. The company is also completing development of MeMed Key™, a point-of-care protein measurement platform, and plans to upscale manufacturing and seek clearance for that device. MeMed intends to expand its pipeline of tests that integrate machine learning with immune-based measurements to address major clinical challenges. The company is led by co‑founders Dr. Eran Eden (CEO) and Dr. Kfir Oved (CTO). MeMed completed an over $70M financing round to support market adoption, product development, manufacturing scale-up, regulatory clearance efforts, and pipeline expansion. MeMed develops host-response diagnostics built on its ImmunoXpert platform, which measures a three-protein signature (TRAIL, IP-10 and C-reactive protein) to differentiate bacterial and viral infections. The technology has been validated in large studies but cannot identify exact pathogen strains. The current instrument requires about two hours and a trained technician, limiting emergency-room use. Co-founders CEO Eran Eden and CTO Kfir Oved are developing a second-generation benchtop device that would use the same three proteins and algorithm to deliver results in under 15 minutes from a drop of blood and be plug-and-play. MeMed's stated clinical goal is to right-size antibiotic use to reduce inappropriate prescriptions and slow antibiotic resistance. The company received DTRA funding to accelerate development of the faster, easier-to-use instrument.